ZYBERNO
Stock Report
Updated Sep 1, 2026

VOLITIONRX LIMITED (VNRX)

Healthcare • NYSE

$0.39

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
VOLITIONRX LIMITED (VNRX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-790.2%)
Return on Capital (Capital Efficiency):CRITICAL (-264.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

VOLITIONRX LIMITED (VNRX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, VNRX generated -$20.76M in Owner Earnings. Capital was deployed as follows: $96.96K invested in capital expenditures. Reinvestment rate: 6.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.39
Market Cap:$4.72M

Valuation Multiples (2)

P/S Ratio:1.92x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$21.40M

Price Action & Momentum (1)

% of 52-Week High:2.6%
B. Profitability Assessment

Return Metrics (4)

ROA:-334.2%
Reinvestment Rate:6.1%
Fundamental Growth Rate (g):-16.3%

Margin Analysis (3)

Operating Margin Ttm:-790.2%
Net Margin Ttm:-1,043.1%
Ebitda Margin:-746.2%

TTM Performance (2)

Operating Margin Ttm:-790.2%
Net Margin Ttm:-1,043.1%

Yield Metrics (2)

Earnings Yield:-$359.14
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-664.0%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):73.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.30x
Quick Ratio:0.30x
Cash Ratio:0.21x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-29.36x
Times Interest Earned:-29.36

Capital Structure (4)

Working Capital:-9,399,692.00
Cash And Cash Equivalents:2,800,000.00
Long Term Debt:$5.98M
Net Debt:$16.68M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $2.46M
Linear Growth: 73.2%
📊 Click to view full VNRX Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$19.42M

Bottom Line Performance (3)

-$25.64M
Income Before Tax:$0.00
Ebitda Ttm:-18,342,423.00

Operating Expenses (5)

Operating Expenses:21,881,923.00
R And D Expense:9,406,555.00
Sga Expense:9,114,762.00
Income Tax Expense:$0.00
Interest Expense:740,388.00

Expense Ratios (3)

R And D To Revenue Percentage:2,359.6%
Sga To Revenue Percentage:2,286.4%
Ebitda Margin:-746.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$8.30M
Current Assets:$4.09M
Ppe Net:3,564,114.00
Goodwill:0.00
Intangible Assets:$305.13K

Liability Structure (4)

Total Liabilities:41,840,346.00
Current Liabilities:13,492,636.00
Long Term Debt:$5.98M
Short Term Debt:$13.50M

Equity & Capital (3)

Equity:-$33.54M
Retained Earnings:-$267.35M
Common Stock:325,000,000.00

Working Capital Items (3)

Accounts Receivable:277,355.00
Inventory:0.00
Accounts Payable:3,564,762.00

Special Items (2)

Contract Liabilities:177,582.00
Stock Based Compensation:224,981.00
C. Cash Flow Analysis

Operating Activities (2)

-$20.67M-$20.76M

Investment Activities (2)

Investing Cash Flow:-$9.21K
Capital Expenditures Ttm:96,964.00

Financing Activities (3)

Financing Cash Flow:$7.62M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:5,173,805.00
Long Term Debt Issuance:$962.72K
Long Term Debt Repayments:$246.19K

Non-Cash Items (1)

Depreciation Amortization Ttm:1,081,456.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.51
-$1.93
Earnings Per Share Ttm:-$2.13

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.20
Operating Cash Flow Per Share:-$1.63

Book Value & Capital (2)

Book Value Per Share:-$2.78
Cash Per Share:0.23

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.32x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:8.86x
Days Sales Outstanding Ttm:41.19

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:529.34
Cash Conversion Cycle:-1,487.15
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$20.76M

Damodaran Growth Analysis (2)

Reinvestment Rate:6.1%
Fundamental Growth Rate (g):-16.3%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):73.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:VNRX
Company Name:VOLITIONRX LIMITED
Sector:Healthcare
Industry:Medical Diagnostics
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:12.04M
Shares Outstanding Basic:12.04M
Shares Outstanding Diluted:9.15M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 14:56:17 UTC
Data Timestamp:2026-08-21T14:13:38.555776
Scroll to Top